Navigation Links
Smallpox vaccine alternative identified
Date:1/7/2008

Irvine, Calif., Jan. 7, 2008 University of California, Irvine infectious disease researchers have shown the effectiveness of a potential alternative to the existing smallpox vaccine that can replace the current biodefense stockpile for this lethal virus.

Philip Felgner and Huw Davies with the Department of Medicine found that the modified vaccinia virus Ankara (MVA) produced the same antiviral response in human and animal studies as the current smallpox vaccine, Dryvax. The study is part of a national effort to develop a replacement for the Dryvax vaccine, which causes serious complications in some people. The results are published in the Journal of Virology.

Studies have shown MVA to be a much safer vaccine product that takes advantage of modern technology, Felgner said. We are pleased that our advanced analytical methods may help to bring an effective and safer vaccine to the public.

Smallpox was declared eradicated worldwide in 1980; the last naturally occurring case in the world was in Somalia in 1977. Routine vaccination against smallpox in the U.S. stopped in 1972, and Dryvax production was halted in 1982.

Both Dryvax and MVA are strains of vaccinia virus, which is related to the smallpox virus. The antibodies created by vaccinia virus infection protect a person against a lethal smallpox infection, making it suitable for use as a vaccine. Unlike smallpox virus, vaccinia creates a very mild infection and is completely safe for healthy individuals.

Although Dryvax was effective during the eradication campaign in the 1960s and 70s, its manufacturing methods are outdated by todays standards, and it is also associated with significant risk of adverse reactions for immune-compromised individuals.

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, identified MVA as a possible candidate to replace Dryvax. MVA was first developed in the 1970s and has been administered to animal species and humans with little or no adverse side effects.

In the study, Felgner and Davies applied blood serum samples taken from both humans and animals given the MVA or Dryvax vaccines to microarray chips containing more than 200 vaccinia virus proteins, on which they simultaneously studied how the serum antibodies responded to all the vaccinia proteins.

The researchers found that these antibody responses were similar in both the animal and human subjects regardless whether they were given MVA or Dryvax, suggesting that MVA contains antiviral properties similar to those in Dryvax.

This similarity is vital, Davies says, because if a vaccine initiates an immune response in humans that matches the one in animals that are protected against lethal pox viruses, then public health officials will have more confidence that the vaccine will be effective in humans.

This is particularly important for vaccines against lethal infections like smallpox, where human clinical trials cannot be done, he added.


'/>"/>

Contact: Tom Vasich
tmvasich@uci.edu
949-824-6455
University of California - Irvine
Source:Eurekalert

Related medicine news :

1. Bavarian Nordic Reports Positive Data from First EUA Enabling Study with IMVAMUNE(R) Smallpox Vaccine Candidate
2. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
3. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
4. Vaccine Stops Alzheimers Brain Tangles
5. Human Papilloma Virus vaccines may decrease chances of oral cancer
6. U.S. Teens Fall Short on Vaccine Coverage
7. Nasal Anthrax Vaccine Proves Effective in Animal Study
8. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
9. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
10. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
11. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... ... The New England Center for Children® (NECC®), a global leader in education ... the Board of Directors. , “The New England Center for Children is honored ... addition to our team,” said Vincent Strully, Jr., President and CEO of The New ...
(Date:9/21/2017)... ... September 21, 2017 , ... Sagora Senior Living, one ... at Kingwood Assisted Living and Memory Care located at 24025 Kingwood Place Drive, ... assisted living apartments, 43 memory care apartments and 23 extended care apartments. Modern ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... Coating System for clients that rely on safety and cleanliness. This unique flooring ... , Silver has been used for centuries for its antimicrobial properties. Unlike antibiotics, ...
(Date:9/20/2017)... ... September 20, 2017 , ... Mirror ... fall event , Look Awesome This Autumn with CoolSculpting®. Scheduled for Thursday, September ... refreshments. , Mirror Mirror Beauty Boutique is Houston’s largest CoolSculpting ...
(Date:9/20/2017)... Trenton, NJ (PRWEB) , ... September 20, 2017 ... ... and a variety of settings, gather for the National Athletic Trainers’ Association Annual ... displayed and case studies presented. It is also when Athletic Trainers are acknowledged ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... ANTONIO , Sept. 6, 2017  Robert G. ... a Pinnacle Professional Member in recognition of his contributions ... Szewc serves as a Nephrologist at the practice of ... emergency medicine, kidney care and hypertension solutions. He has ... 20 years of career experience, as well as expertise ...
(Date:9/6/2017)... N.Y. , Sept. 6, 2017   PDI , ... announced it will host an educational session focused on ... bloodstream infection (CLABSI) prevention at the 2017 Annual Scientific ... which will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/6/2017)... 6, 2017 Eli Lilly and Company (NYSE: ... new data for galcanezumab and lasmiditan, two investigational treatments ... Headache Society (IHC) taking place Sept. 7-10 in ... highlight new, long-term data from an open-label study evaluating ... (120 mg and 240 mg) for the prevention of ...
Breaking Medicine Technology: